StemCells treats first patient in Phase II HuCNS-SC trial for dry AMD
The trial is designed to evaluate both the safety and efficacy of human neural stem cells for the treatment of geographic atrophy (GA), the most advanced form of
ProBio has entered into an exclusive worldwide licensing agreement with South Korean biotechnology firm AbTis to develop and commercialise an early-stage therapeutic antibody asset.
The Phase 1/2 results were previously announced in November 2014. Yotam Nisemblat, BioLineRx Drug Development Director, will present the data in a talk titled BL-7010, a Novel Potential